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Abstract 25 
 26 
Background 27 
Cognitive impairment and dementia following cerebrovascular disease are increasingly 28 
common in the UK. One potential strategy to prevent post-stroke cognitive decline is 29 
multimodal vascular risk factor management. However, its efficacy remains uncertain and its 30 
application in vulnerable patients with incident cerebrovascular disease and early cognitive 31 
impairment has not been assessed. 32 
The primary aim of this study was to assess the feasibility of recruitment and retention of 33 
patients with early cognitive impairment post-stroke or transient ischaemic attack (TIA) to a 34 
trial of enhanced vascular risk factor management combining primary and secondary care.  35 
Methods 36 
In this single centre, open label trial adults with a recent stroke or TIA and mild cognitive 37 
impairment (MCI) were randomised 1:1 to a three-monthly multimodal vascular risk factor 38 
intervention jointly delivered by the trial team and General Practitioner (GP), or control 39 
(defined as usual care from the GP). Chosen risk factors were blood pressure (BP), total 40 
cholesterol, blood glucose (HbA1C) in those with diabetes, and heart rate and adequacy of 41 
anticoagulation in those with atrial fibrillation (AF). Similar patients with normal cognition 42 
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were enrolled in an embedded observational cohort and also received usual care from the 43 
GP. All participants underwent repeat cognitive screening after 12 months.  44 
Results 45 
Seventy three participants were recruited to the randomised trial and 94 to the 46 
observational cohort (21.8% of those screened). From the randomised trial 35/73 (47.9%) 47 
dropped out before final follow-up. In all groups guideline based rates of risk factor control 48 
were mostly poor at baseline and did not significantly improve. The observational cohort 49 
demonstrated greater decline in cognitive test scores at 12 months, with no difference 50 
between the randomised groups. 51 
Conclusions 52 
Recruitment to such a study was feasible, but retention of participants was difficult and rates 53 
of risk factor control did not improve with the intervention. Consequently, successful scaling 54 
up of the trial would require protocol changes to improve participant retention, perhaps 55 
with less reliance on primary care services. Any future trial should include participants with 56 
normal cognition post-stroke as they may be at greatest risk of cognitive decline. 57 
Trial Registration 58 
ISRCTN, ISRCTN42688361. Registered 16 April 2015, https://www.isrctn.com/ISRCTN42688361 59 
 60 
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Background 64 
 4 
Dementia is a significant and increasing health problem in the UK, yet disease modifying 65 
treatments are lacking [1], therefore strategies to prevent cognitive decline are desirable. 66 
Given that cognitive impairment may affect up to 40% of patients following stroke and TIA 67 
[2-4], such strategies may be particularly valuable in this patient group. One potential 68 
strategy is multimodal vascular risk factor control as these risk factors contribute to 69 
recurrent stroke as well as both vascular dementia (VaD) and Alzheimer’s disease [5-7], and 70 
their presence also increases the risk of early cognitive decline progressing to dementia [8]. 71 
Evidence supports the value of good BP control for reducing the risk of subsequent severe 72 
cognitive impairment post-stroke, yet there remains uncertainty about the value of targeting 73 
other vascular risk factors that are relevant to secondary stroke recurrence, especially as 74 
part of a multimodal risk factor approach [5, 9, 10]. Furthermore, whether targeting such a 75 
strategy at patients who already have MCI post-stroke in order to prevent further cognitive 76 
deterioration has not been studied [11-13]. 77 
SERVED Memory (Screening and Enhanced Risk factor management to prevent Vascular 78 
Event related Decline in Memory) was developed to investigate the feasibility of recruiting 79 
patients with MCI post-stroke or TIA to a pragmatic intervention trial of enhanced vascular 80 
risk factor management. It was hypothesised that enhanced risk factor management with a 81 
“treat to target” approach, delivered by a combination of the patient’s GP and a trial team, 82 
would be safe and effective, potentially reducing the risk of progression of MCI compared to 83 
standard GP management alone. The trial also incorporated an embedded non-randomised 84 
observational cohort with the aim of providing epidemiological data regarding the natural 85 
history of cognitive impairment post-stroke or TIA.  86 
  87 
 5 
Methods 88 
SERVED Memory was a single-centre, open-label parallel group randomised controlled 89 
feasibility trial, with embedded non-randomised observational cohort. The trial was granted 90 
ethical approval and was prospectively registered (ISRCTN 42688361). The full trial protocol 91 
has previously been published [14].  92 
In brief, participants were recruited from stroke services at the Norfolk and Norwich 93 
University Hospital (NNUH). Adults with a mild stroke or TIA within the last eight weeks and 94 
Montreal Cognitive Assessment (MoCA) score ≥26 were eligible for the observational cohort, 95 
and those with a MoCA score consistent with MCI (i.e. 20-25 [11, 12]) were eligible for the 96 
randomised controlled trial (RCT). Patients with life expectancy <1 year, diagnosed 97 
depression, or MoCA score <20 were excluded. The MoCA has been validated as a screening 98 
tool and for assessing change in cognition over time in patients with stroke, and has been 99 
shown to be more sensitive than other brief cognitive tests (e.g. Mini Mental State 100 
Examination) in assessing MCI [13, 15, 16]. All participants provided written informed 101 
consent. RCT participants were randomised 1:1 by computer generated randomisation table, 102 
with block size of four, to an intervention or control group. Baseline recording of 103 
demographic data, medication use and compliance, and vascular risk factors was completed. 104 
Measured risk factors were clinic BP, total cholesterol, blood glucose HbA1c in those with 105 
diabetes, and heart rate and anticoagulation adequacy for those with AF. Targets were ideal 106 
BP  <130/80mmHg and standard  <140/90mmHg [17, 18]; total cholesterol <4.0mmol/L 107 
(non-fasting); HbA1C 48-53mmol/mol; heart rate 60-80 beats per minute for those in AF. 108 
Adequate anticoagulation was defined as taking warfarin with INR 2.5-3.0, or a direct oral 109 
anticoagulant, unless contraindicated. Observation and control participants received usual 110 
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care from their GP only. Intervention participants were seen in hospital by the trial team at 111 
three, six, and nine months post-randomisation for risk factor assessment. Results were 112 
passed immediately to the GP for action by phone and letter with the trial team only making 113 
treatment alterations when necessary for patient safety. All participants were followed up at 114 
12 months for assessment of risk factors, medication adherence, adverse events and repeat 115 
MoCA. Baseline frailty was retrospectively assessed from clinical notes using the Rockwood 116 
Frailty Score by a stroke physician blinded to group allocation. 117 
The primary outcome was the assessment of rates of recruitment and retention at 12 118 
months from screening and management logs. Secondary outcomes were (i) rates of risk 119 
factor control to the specified targets in each group (ii) differences in the change in MoCA 120 
score between the intervention and control groups, (iii) change in MoCA score in the 121 
observational arm, and (iv) rates of adverse events (including recurrent stroke) in each 122 
group. 123 
A convenience sample size was based on estimates of the prevalence of cognitive 124 
impairment in patients with incident stroke/TIA [4], the incidence of dementia post-stroke 125 
[19], and estimated cognitive screening rates at NNUH [4]. Based on these estimates target 126 
numbers were 100 in the RCT (50 per group) and 100 in the observational cohort. 127 
 128 
Statistical Analysis 129 
Data were analysed using SPSS (version 25.0) with descriptive statistics only unless specified. 130 
Baseline demographics between the randomised groups were compared using independent 131 
samples t test (for normally distributed continuous variables), independent samples median 132 
test (for non-normally distributed continuous variables), or Chi-square test (for categorical 133 
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variables). Screening logs were assessed to determine the proportion of eligible participants 134 
who consented to participate in the trial, including the proportion that would have been 135 
eligible for the RCT. Management logs were assessed for retention rates in each trial arm 136 
and, where possible, reasons for attrition were identified. Proportions of participants with 137 
controlled risk factors in each group were calculated at baseline and follow-up along with 138 
the frequency of medication changes that occurred during the trial. Changes in MoCA score 139 
from baseline to follow-up for each arm were assessed using a paired samples t test, with 140 
further testing of any difference between the intervention and control arms. A general linear 141 
model, with a normal error term, was used to estimate the effect of the intervention, with a 142 
95% confidence interval, on the 12 month MoCA values. The model included randomisation 143 
group (intervention or control), sex, diagnosis (stroke or TIA) and baseline MoCA value. 144 
Differences in rates of vascular risk factor control between randomised goups at 12 months 145 
were assessed with a Chi-square test. Post-hoc analysis of the difference in baseline frailty 146 
score in retained vs. not retained participants was assessed with a Mann-Whitney U test. 147 
 148 
Results 149 
Trial recruitment ran from November 2015 to July 2017, with final follow-up completed 12 150 
months later. Seven hundred and sixty-seven patients were screened, with 167 (21.8%) 151 
providing consent to participate (Figure 1). Ninety-four participants were included in the 152 
observational cohort and 73 were allocated to the RCT, 37 being randomised to intervention 153 
and 36 to control. Of the remainder screened 362 (47.2%) patients were ineligible and 238 154 
(31.0%) were eligible but declined to participate. Of those declining to participate 18/238 155 
(7.6%) had a MoCA score ≥26, 50/238 (21.0%) had a MoCA score between 20-25, and 156 
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170/238 (71.4%) had not completed cognitive testing at the time of screening. Demographic 157 
details are presented in Table 1. There were no significant differences between the 158 
randomised groups. 159 
Over the course of the trial 35/73 (47.9%) randomised participants did not complete follow-160 
up, 14/36 (38.9%) from the control group and 21/37 (56.8%) from the intervention group.  161 
Withdrawals accounted for 25/35 (71.4%) of participants not completing the trial and 10/35 162 
(28.6%) were lost to follow-up (i.e. did not respond to telephone calls or written requests to 163 
arrange follow-up visits). The trial team took the decision to withdraw six participants before 164 
completion (three died and three were hospitalised for significant health issues). The other 165 
19 participants withdrew of their own volition. Participants were not required to provide a 166 
reason for dropping out, and 7/19 (36.8%) did not wish to further explain their decision. 167 
However, 6/19 (31.6%) reported that their health had deteriorated such that they no longer 168 
wanted to volunteer their time and 6/19 (31.6%) withdrew because they did not wish to 169 
travel to the hospital for follow-up visits (despite the offer of reimbursement for costs or taxi 170 
services).  171 
Average MoCA scores declined significantly in the observation cohort (-1.7 points [95%CI -172 
2.3 to -1.1, p<0.0001]), but not in the intervention (-0.6 points [95%CI -2.3 to 1.1, p=0.45]) or 173 
control groups (-0.5 points [95%CI -2.1 to 1.1, p=0.45]). From the general linear model to 174 
estimate the effect of the intervention the mean 12 month MoCA for the Intervention group 175 
was 0.664 units lower than for Control, with 95% confidence interval for the difference 176 
(intervention minus control) being -2.69 to 1.37. Baseline rates of control for all risk factors 177 
were low across all trial groups, irrespective of BP threshold value (Tables 2 and 3). There 178 
were improvements in the rates of control for cholesterol and adequate anticoagulation in 179 
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all trial groups at 12 months, however, BP control rates had declined and no changes were 180 
seen in relation to heart rate and HbA1C (Table 4). The proportions of participants on 181 
treatment for the selected risk factors were largely unaltered after 12 months, with the 182 
exception of increases in statin use and the prescription of anticoagulants. Rates of adverse 183 
events and recurrent stroke were similar between the randomised groups (Table 5). Median 184 
baseline frailty scores were lower in those who completed the trial compared to those who 185 
did not (median 4.0 [IQR 3.0, 6.0] and 5.0 [IQR 4.0, 6.0] respectively, p=0.05). 186 
 187 
Discussion 188 
At present it is unclear whether control of multiple vascular risk factors can prevent further 189 
cognitive decline in vulnerable patients with a recent cerebrovascular event [5, 9, 20]. Firstly, 190 
trials of antihypertensive therapy to prevent cognitive decline have been inconsistent, 191 
possibly limited by high rates of treatment in placebo groups, poor participant retention, and 192 
short follow-up [5]. However, a large trial in patients with stroke suggested a benefit to 193 
treatment, with this finding corroborated by subsequent meta-analysis [5, 9, 10]. Secondly, 194 
two randomised controlled trials have assessed the use of statins and found no benefit on 195 
cognition despite reduction in cholesterol levels [21]. Thirdly, in the ADVANCE study 196 
intensive blood glucose control in type 2 diabetics successfully reduced microvascular 197 
complications, but did not reduce rates of dementia [5]. However, given that recurrent 198 
stroke is an important factor in the development of post-stroke dementia [2], it remains 199 
plausible that multimodal vascular risk factor intervention in this patient group is valuable, 200 
with a recent review concluding that such interventions are effective at preventing dementia 201 
in the general population [22]. 202 
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SERVED Memory aimed to test the feasibility of conducting such multimodal, guideline 203 
based, risk factor management in a pragmatic trial combining primary and secondary care 204 
input. We demonstrated a recruitment rate of >20% of patients screened, suggesting that 205 
recruitment of patients with MCI associated with cerebrovascular disease to such a trial is 206 
possible. Although short of the recruitment target, the numbers entering the trial support its 207 
feasibility, especially given the proportion of patients with a MoCA score 20-25, or unknown 208 
at the point of screening, who declined to participate. However, nearly half of participants in 209 
the RCT arms did not complete follow-up, with this retention difficulty being partly related 210 
to frailty status. Alterations to the protocol may alleviate these difficulties, for example 211 
carrying out trial visits in the patients’ homes, using online assessments, or treatment 212 
changes being made directly by the trial team rather than relaying information to the GP. 213 
Such supported self-management strategies are deliverable in this patient population as 214 
evidenced by the TEST-BP trial [23], but these changes would inevitably increase the 215 
complexity and cost of conducting the trial. With regard to reducing the intervention’s 216 
reliance on primary care, the data suggests that the increased risk factor monitoring 217 
provided by the intervention may not have translated into enhancements in treatment. This 218 
may be due to a degree of treatment inertia, but may also relate to additional factors not 219 
captured by our data, for example patient choice, treatment side effects, or a more 220 
pragmatic approach to treatment in individuals with frailty. Although this trial was supported 221 
by a GP applicant, more involvement of primary care in future trial design would be valuable 222 
to explore how the intervention as envisaged could be improved.  223 
In terms of the secondary objective of assessing the effect of the intervention we did not 224 
show a between-group difference in change in MoCA score over 12 months. Interestingly a 225 
greater decline in cognitive scores was seen in the observational cohort. These findings are 226 
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in keeping with the results of two similar trials in patients with recent stroke but no evidence 227 
of early cognitive decline or MCI. Firstly, Ihle-Hansen et al. (N=195) demonstrated no 228 
difference in incident cognitive impairment or dementia at 12 months with a multimodal 229 
intervention (including treatment of BP, cholesterol, AF, and diabetes, and cardiovascular 230 
lifestyle advice) delivered at three and six months post-randomisation compared to usual GP 231 
care [24]. Secondly, Matz et al. (N=202) reported no significant difference in cognitive test 232 
scores at 24 months between those treated with a multimodal vascular risk factor 233 
intervention (including BP treatment, cardiovascular lifestyle advice, and cognitive training) 234 
and usual care [25]. Conversely, the FINGER trial recruited a population of older adults with 235 
cardiovascular risk factors (but only 5% with prior stroke) and randomised them to a 236 
multimodal intervention (including vascular risk factor monitoring similar to this trial) or 237 
usual care. Over a two year follow-up period there was significantly less cognitive decline in 238 
the intervention group [26, 27]. Similarly, another primary care based trial of a multimodal 239 
intervention aimed at treating cardiovascular risk factors, compared to usual care, 240 
demonstrated both improvements in treatment of the relevant risk factors and a reduction 241 
in the need for long-term institutional care with the intervention [28]. Given these positive 242 
trials, and the small sample sizes and short follow-up duration of existing studies of 243 
multimodal vascular risk factor intervention in stroke patients, further trials may be 244 
warranted. 245 
The main strength of this trial is the enrolment of patients with early cognitive decline, who 246 
are at increased risk of developing dementia, and in whom this preventive strategy has not 247 
previously been assessed. A further strength is the use of a pragmatic real-world design, 248 
although this also served to highlight challenges in the optimisation of care for secondary 249 
stroke prevention that would need addressing in any future trial. An important limitation is 250 
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that we did not consult GP’s directly as to why treatment targets were not being met, but it 251 
may reflect ongoing debate about the most appropriate risk factor targets (especially in 252 
older patients) [6, 7, 29], or excessive demands from the existing primary care workload. It is 253 
therefore difficult to know whether the lack of impact of the intervention on vascular risk 254 
factor control was related to deficiencies in the intervention itself, or was related to other 255 
important trial limitations such as small sample size, short duration of follow-up, or the high 256 
dropout rate. This is potentially a missed opportunity to glean information that could have 257 
helped to improve the intervention in any future trial. The assessment of the secondary trial 258 
objectives was also limited by the small sample size and participant dropout. Furthermore, 259 
due to the lack of ethnic diversity in the trial population any findings may lack 260 
generalisability.  261 
 262 
Conclusions 263 
Although the current protocol would not be feasible to deliver a definitive multi-centre trial 264 
due to difficulties with participant retention and application of the intervention, a successful 265 
further trial may be possible with protocol alterations as discussed. In addition, the findings 266 
of the epidemiological observation cohort suggest that such a trial should include patients 267 
with normal cognition and MCI following their cerebrovascular event, as all are at risk of 268 
further cognitive decline. 269 
 270 
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Figures and Tables 381 
Figure 1: CONSORT flow diagram 382 
Table 1: Demographic data for each group at baseline.  383 
  Observation Control Intervention P 
value N  94 36 37 
Symptom onset 
to 
randomisation 
(days) 
 
25.7 (20.1) 22.6 (20.9) 17.8 (19.7) 0.42 
Age (years)  72.1 (10.9) 74.9 (9.2) 75.0 (12.0) 0.97 
Gender (male)  59 (62.8%) 23 (63.9%) 27 (73.0%) 0.40 
Ethnicity (White 
British) 
 
94 (100.0%) 36 (100.0%) 37 (100.0%) - 
Smoking status Non-smoker 38 (40.4%) 17 (47.2%) 26 (70.3%) 
0.07 
Ex-smoker 29 (30.9%) 14 (38.9%) 10 (27.0%) 
Current 
smoker 
6 (6.4%) 5 (13.9%) 1 (2.7%) 
Alcohol 
(units/wk) 
 
0.0 (0.0, 15.8) 
3.0 (0.0, 
20.0) 
2.0 (0.0, 9.0) 0.73 
Diagnosis TIA 40 (42.6%) 11 (30.6%) 10 (27.0%) 
0.74 
Stroke 54 (57.4%) 25 (69.4%) 27 (73.0%) 
OCSP 
classification 
LACS 27 (50.0%) 9 (36.0%) 11 (40.7%) 
0.67 
PACS 13 (24.1%) 13 (52.0%) 11 (40.7%) 
TACS 0 (0.0%) 0 (0.0%) 0 (0.0%) 
POCS 14 (25.9%) 3 (12.0%) 5 (18.5) 
Past medical 
history 
AF 25 (26.6%) 6 (16.7%) 10 (27.0%) 0.29 
Diabetes 19 (20.2%) 7 (19.4%) 5 (13.5%) 0.49 
IHD 11 (11.7%) 4 (11.1%) 6 (16.2%) 0.53 
Stroke 44 (46.8%) 12 (33.3%) 21 (56.8%) 0.05 
TIA 36 (38.3%) 6 (16.7%) 7 (18.9%) 0.80 
Hypertension 53 (56.4%) 20 (55.6%) 25 (67.6%) 0.29 
Rockwood 
Frailty Score 
 
4.0 (3.0, 6.0) 
5.0 (4.0, 
6.0) 
6.0 (4.5, 6.0) 0.33 
MoCA  27.4 (1.4) 23.4 (1.4) 23.2 (1.5) 0.61 
Clinic BP Systolic 147.3 (20.5) 148.1 (21.0) 145.2 (19.5) 0.54 
 17 
(mmHg) Diastolic 79.6 (10.5) 78.9 (11.5) 81.8 (12.5) 0.30 
Total 
Cholesterol 
(mmol/L) 
 
4.9 (1.2) 4.9 (1.2) 4.6 (1.4) 0.34 
Heart rate 
(beats per min)† 
 
76.6 (18.9) 75.9 (16.8) 80.4 (10.2) 0.98 
On 
anticoagulation† 
 
10/25 (40.0%) 3/6 (50.0%) 
3/10 
(30.0%) 
0.42 
HbA1C 
(mmol/mol)‡ 
 52.5 (47.3, 
69.5) 
49.5 (43.0, 
82.3) 
73.0 (51.8, 
106.3) 
0.89 
Data presented are mean (SD), median (IQR), or frequency (%). P values represent 384 
hypothesis testing for differences between the randomised groups (control vs. intervention). 385 
†Only those with AF 386 
‡Only those with diabetes 387 
 388 
Table 2: Rates of control for secondary prevention measures by study group. 389 
 Observation 
(N=71) 
Control (N=22) Intervention 
(N=16) P 
value 
Baseline 
12 
months 
Baseline 
12 
months 
Baseline 
12 
months 
Antiplatelet use 
50/71 
(70.4%) 
51/71 
(71.8%) 
17/22 
(77.3%) 
15/22 
(68.2%) 
10/16 
(62.5%) 
10/16 
(62.5%) 
0.72 
Systolic BP 
(mmHg) 
147.8 
(21.2) 
152.1 
(18.1) 
148.3 
(20.3) 
152.4 
(23.3) 
143.7 
(14.2) 
156.1 
(19.4)  
 
Diastolic BP 
(mmHg) 
80.3 
(10.4) 
84.5 
(10.9) 
80.2 
(10.8) 
81.1 
(14.3) 
82.7 
(10.0) 
88.9 
(12.5) 
 
BP 
<130/80mmHg 
7/71 
(9.9%) 
2/71 
(2.8%) 
2/22 
(9.1%) 
1/22 
(4.5%) 
2/16 
(12.5%) 
0/16 
(0.0%) 
0.39 
BP 
<140/90mmHg 
24/71 
(33.8%) 
19/71 
(26.8%) 
7/22 
(31.8%) 
5/22 
(22.7%) 
6/16 
(37.5%) 
2/16 
(12.5%) 
0.42 
Total Cholesterol 
(mmol/L) 
4.9 (1.1) 4.4 (1.0) 4.9 (1.0) 4.3 (1.0) 4.1 (0.8) 3.9 (1.0)  
Total Cholesterol 
<4.0mmol/L 
16/71 
(22.5%) 
28/71 
(39.4%) 
4/22 
(18.2%) 
10/22 
(45.5%) 
8/16 
(50.0%) 
10/16 
(62.5%) 
0.30 
Heart rate (beats 
per min)1, 
75.7 
(12.1) 
74.5 
(12.3) 
68.4 
(13.8) 
72.3 
(18.9) 
78.3 
(5.5) 
71.1 
(10.5) 
 
HR 60-80bpm1 10/21 
(47.6%) 
12/23 
(52.2%) 
2/3 
(66.7%) 
2/6 
(33.3%) 
3/5 
(60.0%) 
5/7 
(71.4%) 
0.72 
Adequate 
anticoagulation1,2 
8/21 
(38.1%) 
18/23 
(78.3%) 
3/3 
(100.0%) 
5/6 
(83.3%) 
1/5 
(20.0%) 
6/7 
(85.7%) 
1.00 
HbA1C 
mmol/mol3 
51.0 
(44.3, 
64.3) 
49.0 
(44.0, 
69.3) 
80.0 (-) 66.0 (-) 53.5 (-) 62.0 (-)  
 18 
HbA1C 48-
53mmol/mol3 
5/15 
(33.3%) 
4/17 
(23.5%) 
0/3 
(0.0%) 
0/3 
(0.0%) 
1/2 
(50.0%) 
1/3 
(33.3%) 
0.18 
Average values and rates of control for secondary vascular prevention measures at baseline 390 
and 12 months by study group (restricted to participants who completed follow-up). Data 391 
presented are mean (SD), median (IQR), or frequency (%). P values represent testing for 392 
differences in rates of control at 12 months between the randomised groups (control vs. 393 
intervention). 394 
1Only those with AF 395 
2INR 2.5-3.0 or on a DOAC 396 
3Only those with diabetes 397 
 398 
Table 3: Rates of secondary prevention control at baseline in all participants. 399 
 
Observation 
(N=94) 
Control 
(N=36) 
Intervention 
(N=37) 
Antiplatelet use 68/94 (72.3%) 27/36 (75.0%) 24/37 (64.9%) 
Systolic BP (mmHg) 147.3 (20.5) 148.1 (21.0) 145.2 (19.5) 
Diastolic BP (mmHg) 79.6 (10.5) 78.9 (11.5) 81.8 (12.5) 
BP <130/80mmHg 10/94 (10.6%) 6/36 (16.7%) 6/37 (16.2%) 
BP <140/90mmHg 35/94 (37.2%) 12/36 (33.3%) 15/37 (40.5%) 
Total Cholesterol 
(mmol/L) 
4.9 (1.2) 4.9 (1.2) 4.6 (1.4) 
Total Cholesterol 
<4.0mmol/L 
22/94 (23.4%) 7/36 (19.4%) 14/37 (37.8%) 
Heart rate (beats 
per min)1, 
76.6 (18.9) 75.9 (16.8) 80.4 (10.2) 
HR 60-80bpm1 11/25 (44.0%) 3/6 (50.0%) 5/10 (50.0%) 
Adequate 
anticoagulation1,2 
10/25 (40.0%) 3/6 (50.0%) 3/10 (30.0%) 
HbA1C mmol/mol3 52.5 (47.3, 69.5) 49.5 (43.0, 82.3) 73.0 (51.8, 106.3) 
HbA1C 48-
53mmol/mol3 
6/19 (31.6%) 1/7 (14.3%) 1/5 (20.0%) 
Average values and rates of control for secondary vascular prevention measures at baseline 400 
by study group (all participants). Data presented are mean (SD), median (IQR), or frequency 401 
(%). 402 
1Only those with AF 403 
2INR 2.5-3.0 or on a DOAC 404 
3Only those with diabetes 405 
 406 
Table 4: Rates of vascular risk factor treatment at baseline and 12 months. 407 
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 Observation (N=71) Control (N=22) Intervention (N=16) 
Baseline 
12 
months 
Baseline 
12 
months 
Baseline 
12 
months 
Antihypertensive 
medication (at 
least one agent) 
Proportion 
treated 
46/71 
(64.8%) 
50/71 
(70.4%) 
14/22 
(63.6%) 
16/22 
(72.7%) 
12/16 
(75.0%) 
14/16 
(87.5%) 
Treatment 
increased 
- 
12/71 
(16.9%) 
- 
8/22 
(36.4%) 
- 
6/16 
(37.5%) 
Treatment 
decreased 
- 
12/71 
(16.9%) 
- 
1/22 
(4.5%) 
- 
2/16 
(12.5%) 
Treatment 
unchanged 
- 
47/71 
(66.2%) 
- 
13/22 
(59.1%) 
- 
8/16 
(50.0%) 
Statin or other 
lipid lowering 
medication 
Proportion 
treated 
52/71 
(73.2%) 
56/71 
(78.9%) 
20/22 
(90.9%) 
20/22 
(90.9%) 
9/16 
(56.3%) 
10/16 
(62.5%) 
Treatment 
increased 
- 
14/71 
(19.7%) 
- 
2/22 
(9.1%) 
- 
3/16 
(18.7%) 
Treatment 
decreased 
- 
7/71 
(9.9%) 
- 
2/22 
(9.1%) 
- 
4/16 
(25.0%) 
Treatment 
unchanged 
- 
50/71 
(70.4%) 
- 
18/22 
(81.8%) 
- 
9/16 
(56.3%) 
Rate lowering 
medication (e.g. 
beta blocker) 
Proportion 
treated 
10/21 
(47.6%) 
11/23 
(47.8%) 
0/3 
(0.0%) 
4/6 
(66.7%) 
3/5 
(60.0%) 
5/7 
(71.4%) 
Treatment 
increased 
- 
0/23 
(0.0%) 
- 
4/6 
(66.6%) 
- 
3/7 
(42.9%) 
Treatment 
decreased 
- 
2/23 
(8.7%) 
- 
0/6 
(0.0%) 
- 
0/7 
(0.0%) 
Treatment 
unchanged 
- 
21/23 
(91.3%) 
- 
2/6 
(33.4%) 
- 
4/7 
(57.1%) 
Warfarin or 
direct oral 
anticoagulant 
Proportion 
treated 
13/21 
(61.9%) 
19/23 
(82.6%) 
3/3 
(100.0%) 
5/6 
(83.3%) 
3/5 
(60.0%) 
6/7 
(85.7%) 
Treatment 
increased 
- 
8/23 
(34.8%) 
- 
2/6 
(33.4%) 
- 
3/7 
(42.9%) 
Treatment 
decreased 
- 
2/23 
(8.7%) 
- 
0/6 
(0.0%) 
- 
1/7 
(14.2%) 
Treatment 
unchanged 
- 
13/23 
(56.5%) 
- 
4/6 
(66.6%) 
- 
3/7 
(42.9%) 
Oral diabetic 
medications or 
insulin 
Proportion 
treated 
8/15 
(53.3%) 
8/17 
(47.1%) 
2/3 
(66.7%) 
2/3 
(66.7%) 
2/2 
(100.0%) 
3/3 
(100.0%) 
Treatment 
increased 
- 
0/17 
(0.0%) 
- 
0/3 
(0.0%) 
- 
1/3 
(33.4%) 
Treatment 
decreased 
- 
0/17 
(0.0%) 
- 
0/3 
(0.0%) 
- 
0/3 
(0.0%) 
Treatment 
unchanged 
- 
17/17 
(100.0%) 
- 
3/3 
(100.0%) 
- 
2/3 
(66.6%) 
Rates of vascular risk factor treatment at baseline and 12 months by study group and 408 
changes during the trial (restricted to participants who completed follow-up). Data 409 
presented are frequency (%). 410 
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 411 
Table 5: Adverse events. 412 
 Observation Control Intervention 
Serious adverse events 36 25 24 
Deaths 3 1 2 
Recurrent stroke/TIA 
events 
7 2 5 
Withdrawals due to ill 
health (other than 
recurrent stroke/TIA) 
2 2 0 
Rates of serious adverse events, including deaths and recurrent stroke events, by study 413 
group. 414 
